Salivary gland scinti‐scanning with technetium 99m pertechnetate

Abramson, Allan L.; Levy, Lester M.; Goodman, Merrill; Attie, Joseph N.

doi:10.1288/00005537-196906000-00005

Cited by 50 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the process of concentrating the radioactive iodine, the salivary glands are exposed to the damaging effects of irradiation. Therefore, serous and mucous cells are susceptible to the deleterious effects of ionizing radiation [5,14].…”

Section: Salivary Glands and Uptake Of The Radioactive Iodinementioning

confidence: 99%

RETRACTED ARTICLE: Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

Jeong

Lee

2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Radioactive iodine ((131)I) is accumulated in the thyroid tissue and plays an important role in the treatment of differentiated papillary and follicular cancers after thyroidectomy. Simultaneously, (131)I is concentrated in the salivary glands and secreted into the saliva. Dose-related damage to the salivary parenchyma results from the (131)I irradiation. Salivary gland swelling and pain, usually involving the parotid, can be seen. The symptoms may develop immediately after a therapeutic dose of (131)I and/or months later and progress in intensity with time. In conjunction with the radiation sialadenitis, secondary complications reported include xerostomia, taste alterations, infection, increases in caries, facial nerve involvement, candidiasis, and neoplasia. Prevention of (131)I sialadenitis may involve the use of sialogogic agents to hasten the transit time of the radioactive iodine through the salivary glands. However, studies are not available to delineate the efficacy of this approach. Treatment of the varied complications that may develop encompass numerous approaches and include gland massage, sialogogic agents, duct probing, antibiotics, mouthwashes, good oral hygiene, and adequate hydration. Recently interventional sialoendoscopy has been introduced an effective tool for the management of patients with (131)I-induced sialadenitis that is unresponsive to medical treatment.

show abstract

Section: Salivary Glands and Uptake Of The Radioactive Iodinementioning

confidence: 99%

RETRACTED ARTICLE: Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

Jeong

Lee

2010

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…Although all salivary glands are involved in the transport of the radioactive iodine into the saliva, the parotid glands are most active and their serous cells are more susceptible than mucous acini to the deleterious e ects of ionizing radiation. Therefore, the serous parotid gland will demonstrate a more intense radiation sialadenitis than the mixed mucous and serous cell-containing submandibular and sublingual salivary glands (Abramson 1969;Rigler 1955). Serous cells are particularly concerned with secretion of salts and zymogen, the precursor of amylase.…”

Section: Irradiation E Ects Of High Dose Radioactive Iodine On Salivamentioning

confidence: 99%

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Xie²,

Chen³

et al. 2009

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Therefore, the serous parotid gland will demonstrate a more intense radiation sialadenitis than the mixed mucous and serous cell-containing submandibular and sublingual salivary glands. [5,14] Serous cells are particularly concerned with secretion of salts and zymogen, the precursor of amylase. The mucous cells secrete mucin, a lubricant that eases swallowing and act as a protective oral mucosal barrier.…”

Section: Salivary Glandsmentioning

confidence: 99%

Radioactive Iodine and the Salivary Glands

Mandel

2003

Thyroid

320

260

View full text Add to dashboard Cite

Radioactive iodine ((131)I) targets the thyroid gland and has been proven to play an effective role in the treatment of differentiated papillary and follicular cancers. Simultaneously, this radioisotope hones in on the salivary glands where it is concentrated and secreted into the saliva. Dose related damage to the salivary parenchyma results from the (131)I irradiation. Salivary gland swelling and pain, usually involving the parotid, can be seen. The symptoms may develop immediately after a therapeutic dose of (131)I and/or months later and progress in intensity with time. In conjunction with the radiation sialadenitis, secondary complications reported include xerostomia, taste alterations, infection, increases in caries, facial nerve involvement, stomatitis, candidiasis, and neoplasia. Prevention of the (131)I sialadenitis may involve the use of sialogogic agents to hasten the transit time of the radioactive iodine through the salivary glands. However, studies are not available to delineate the efficacy of this approach. Recently, amifostine has been advocated to prevent the effects of irradiation. Treatment of the varied complications that may develop encompass numerous approaches and include gland massage, sialogogic agents, duct probing, antibiotics, mouthwashes, good oral hygiene, and adequate hydration.

show abstract

Salivary gland scinti‐scanning with technetium 99m pertechnetate

Cited by 50 publications

References 9 publications

RETRACTED ARTICLE: Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

RETRACTED ARTICLE: Radiation Sialadenitis Induced by High-dose Radioactive Iodine Therapy

Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer

Radioactive Iodine and the Salivary Glands

Contact Info

Product

Resources

About